Vol 7 Nol2 JanJune JulyDec 2004 Junaid Mahmood Alam et a1 Univ Sample Collection Results Blood 5 ml was collected in clot activated tubes Serum was separated and store ID: 939492
Download Pdf The PPT/PDF document "J Baqai Med" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Vol. 7, Nol&2 Jan-June / July-Dec 2004 Junaid Mahmood Alam et a1 J. Baqai Med. Univ. Sample Collection: Results: * Blood (5 ml) was collected in clot activated tubes * Serum was separated and stored at -lO°C until analyzed Analysis and Calculation: * All CEA analysis was performed in duplicates by Automated ELlSA techniques with two -point calibration and controls with definite cut-off values on Elecsys 101 0 (Roche Diagnostics, Basil) automated immuno-analyzer. +
For accuracy purpose, CEA values greater than two folds of 10 nglml were considered significant. Normal range is between 2.5-5.0 ng/ml. * All data were statistically compared with student's t tests with P 0.01. Data of patients are also presented in the form of percentage occurrence for clarity. The results are in Table 1-11 and Figures 1-4. Briefly, 86 patients, 70 (81.39%) males and 16 (18.60%) females, were included in the study with age range of 36 to 81 years. Out of 70 males,
23 (32.80%) have malignant conditions and exhibited elevated levels of CEA (66 nglml to 230 ng/ml; mean = 18921 8 ng/ml), whereas 47 have non- malignant complications with normal or non-significant �( 10 ngml but 20 ng/ml) CEA concentrations. Malignant conditions were determined to be pancreatic (1 3.04%), gastric (26.08%), colorectal(43.47%) and hepatic (1 7.39%) cancers. In female group, 10 (62.50%) were diagnosed with malignant condition of pancreatic (1 0%)
, gastric (20%) and colorectal (70%) cancers. Non-malignant conditions were found to be hepatitis, cirrhosis, pancreatitis (acute and obstructive) and gastritis. In present study all malignant conditions, either metastasizing or not, showed significantly elevated levels of CEA. In male-malignant cancer patents' groups, average CEA values were 92220 nglml, 1 18k2 1 ng/ml, 192216 ng/ml and 7625 ngml for pancreatic, gastric, colorectal and hepatic cancers, respectively. Similar
ly in females elevated levels of CEA were noted in pancreatic (69 ng/ml), gastric (139222 ng/ml) and CRC (1 41 +I 6 nglml). Table I: Registry of male patients diagnosedwith malignant and non-malignant conditions and assessed for serum CEA concentrations. Age group (Ym) 46-69 49-66 46-65 50-68 51-60 42-63 44-60 49-70 50-66 51-69 Malignant ---- Yes Yes Yes Yes --- Nil Nil Nil Nil Type of Conditions than Elevated levels CEA conc [ng/mQ 189218 ----- 92220 118 221 192 2 f6 76
25 4.4 f: 1.8 No of patients potal n = 701 23 [23/70] A) Disease other malignancy 8) Non-malignant tumors ---- --- -- --- ---- A A A A+B % 32.80 I) Pancreatic cancer 11) Gastric cancer 111) Colorectal cancer IV) Hepatic cancer Normal levels I) Hepatitis 11) Cirrhosis 111) Pancreatitis IV) Gastritis 03 [03/23] 06 [OW231 10 [10/23] 04 [04/23] 4 7 [4 7/70] 05 LOU4 71 I 0 [I 0/4 71 06 [OW4 71 26 [2W47] 13.04 26.08 43.47 17.39 67.14 10.60 21.27 12.76 5